Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 8/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.33 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30795778 | 0.85 | EPHX1 (0.38) | EPHX1CYP1A2CYP2D6PKMSMN1; SMN2 | |
| SCHEMBL30795605 | 0.82 | EPHX1 (0.40) | EPHX1CYP1A2CYP2D6PKMSMN1; SMN2 | |
| SCHEMBL30795511 | 0.79 | SLC6A2 (0.40) | EPHX1CYP1A2CYP2D6PKMSMN1; SMN2 | |
| SCHEMBL7507142 | 0.73 | CYP1A2 (0.42) | EPHX1CYP1A2CYP2D6PKMSMN1; SMN2 | |
| SCHEMBL3458611 | 0.70 | EPHX1 (0.43) | EPHX1CYP1A2CYP2D6PKMSMN1; SMN2 | |
| SCHEMBL16963125 | 0.69 | GSR (0.49) | CYP1A2CYP2D6SMN1; SMN2MEN1KMT2A | |
| SCHEMBL27835347 | 0.69 | TAAR1 (0.46) | — | |
| SCHEMBL28343846 | 0.67 | PABPC1 (0.51) | KMT2A | |
| SCHEMBL28343847 | 0.67 | PABPC1 (0.51) | KMT2A | |
| SCHEMBL15716450 | 0.66 | GAA (0.46) | EPHX1CYP1A2CYP2D6PKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |